Abstract
Oncology drug development is an increasingly complex effort involving multiple stakeholders on a global scale. This review summarizes the role of the United States Food and Drug Administration (USFDA) and its office of oncology drugs in the regulation of anticancer drug therapies. The regulatory history of FDAs mission will be summarized. The FDAs role from first-in-human dose finding studies to trials designed to evaluate efficacy, as well as post-marketing considerations will be outlined. During this entire process, the FDA is committed to productive interactions with all its stakeholders, including the public, the pharmaceutical industry, academia, other government agencies and patient advocacy groups.
Keywords: investigational drug application (IND), post-marketing, new drug application (NDA), Clinical trials, Drug development
Current Cancer Therapy Reviews
Title: The Role of FDA in the Regulation of Anti-Cancer Drugs
Volume: 2 Issue: 4
Author(s): Ramzi N. Dagher and Richard Pazdur
Affiliation:
Keywords: investigational drug application (IND), post-marketing, new drug application (NDA), Clinical trials, Drug development
Abstract: Oncology drug development is an increasingly complex effort involving multiple stakeholders on a global scale. This review summarizes the role of the United States Food and Drug Administration (USFDA) and its office of oncology drugs in the regulation of anticancer drug therapies. The regulatory history of FDAs mission will be summarized. The FDAs role from first-in-human dose finding studies to trials designed to evaluate efficacy, as well as post-marketing considerations will be outlined. During this entire process, the FDA is committed to productive interactions with all its stakeholders, including the public, the pharmaceutical industry, academia, other government agencies and patient advocacy groups.
Export Options
About this article
Cite this article as:
Dagher N. Ramzi and Pazdur Richard, The Role of FDA in the Regulation of Anti-Cancer Drugs, Current Cancer Therapy Reviews 2006; 2 (4) . https://dx.doi.org/10.2174/157339406778699196
DOI https://dx.doi.org/10.2174/157339406778699196 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Analogues of Mycophenolic Acid
Mini-Reviews in Medicinal Chemistry Management of Endometrial Cancer: A Review
Reviews on Recent Clinical Trials The Need for Calcium Channels in Cell Proliferation
Recent Patents on Anti-Cancer Drug Discovery Anti-Inflammatory Agents in Ageing and Age-Associated Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Breakthrough Pain
Current Drug Therapy Editorial [Hot Topic: Target Therapy in Brain Tumours and Metastases (Guest Editors: M. Caraglia and R. Addeo)]
Current Cancer Drug Targets Review of the Third Domain Receptor Binding Fragment of Alphafetoprotein (AFP): Plausible Binding of AFP to Lysophospholipid Receptor Targets
Current Drug Targets Withdrawal Notice: Computational Druglikeness Assessment, Synthesis, Characterization and In vitro Biological Activity Evaluation of some Novel Mixed Metal Complexes of 2-(butan-2-ylidene) Hydrazinecarbothioamide
Combinatorial Chemistry & High Throughput Screening Chemoprevention Strategies for High Risk Women
Current Women`s Health Reviews Promises and Challenges of Adult Stem Cells in Cancer Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Should the Incorporation of Structural Alerts be Restricted in Drug Design? An Analysis of Structure-Toxicity Trends with Aniline-Based Drugs
Current Medicinal Chemistry Anti-Angiogenic Therapy in Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Cholesterol: A Prelate in Cell Nucleus and its Serendipity
Current Molecular Medicine Targeting the Akt Kinase to Modulate Survival, Invasiveness and Drug Resistance of Cancer Cells
Current Medicinal Chemistry Meet Our Editorial Board Member
Current Medicinal Chemistry Adalimumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Volatile Organic Compounds Trapping from Gaseous Samples on the Basis of Co-Liquefaction with Organic Solvent for Gas Chromatographic Analysis
Current Analytical Chemistry Hepatic Diseases Related to Triglyceride Metabolism
Mini-Reviews in Medicinal Chemistry Nitric Oxide-Releasing Biomaterials for Biomedical Applications
Current Medicinal Chemistry Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein - Protein Interactions in Cancer: Mechanistic View
Current Cancer Drug Targets